Skip to content
Review Open access

Therapy-Induced Senescence in Cancer Treatment Resistance: Mechanisms, Evidence, and Translational Opportunities

Sep 2026 · Cancers · Vol 18 · 0 citations · 179 references
Medicine

TL;DR

Overall, current data support a context-dependent role for persistent senescence in treatment resistance, but do not establish TIS as a universal or independent cause of therapeutic failure.

Abstract

Simple Summary Cancer treatments such as chemotherapy, radiotherapy, targeted therapy, and, in selected settings, immunotherapy can induce cellular senescence, a state characterized by durable cell-cycle withdrawal. Senescence may initially contribute to tumor control, but persistent senescent cells can also modify the tumor microenvironment, alter inflammatory signaling, and support tumor-cell plasticity or survival. Importantly, senescent cells may be present before treatment as a consequence of aging, chronic inflammation, environmental stress, fibrosis, or oncogenic signaling. This review therefore considers therapy-induced senescence (TIS) within its broader tissue context and examines evidence linking senescence-associated phenotypes to treatment response, resistance, and recurrence. We distinguish mechanistic and preclinical evidence from clinical associations and from clinically validated findings, and we discuss the limitations of current senescence biomarkers. Finally, we evaluate senolytic, senomorphic, and sequential “one–two punch” strategies, emphasizing that most therapeutic evidence remains preclinical and that biomarker-guided treatment timing and patient selection remain unresolved.

Read PDF

Similar papers

Review Open access Aug 2026

Targeting Cellular Senescence for Cancer Therapy

The biological mechanisms regulating cellular senescence are summarized, its contrasting roles in cancer development are highlighted, emerging therapeutic approaches are discussed, and current challenges and future directions for translating senescence-based therapies into clinical oncology are outlined.

Awateef Fatima, Saba Yousuf · 0 citations
Review Open access Sep 2026

Therapy-induced senescence in breast cancer and cardiovascular disease: a double-edged biological process

Therapy-induced senescence (TIS) has emerged as a central biological response to anticancer therapies, extending beyond tumor suppression to influence long-term tissue homeostasis, cardiovascular (CV) remodeling, and accelerated biological aging. In breast cancer (BC), chemotherapy, radiotherapy, targeted therapies, an...

Eugenia Belcastro, G. Fanelli, Maria Luisa Schiavone et al. · 0 citations
Review Open access Sep 2026

Therapy-induced senescent cancer-associated fibroblasts in cervical cancer: Mechanisms of treatment resistance and therapeutic opportunities

Therapy-induced sCAF offers a plausible framework for understanding post-CCRT microenvironmental remodeling and treatment resistance in cervical cancer, and the mechanisms by which they may contribute to treatment resistance are evaluated.

Jing-Yang Lan, Cheng-Ming Tian, Tong Wang et al. · 0 citations
Review Sep 2026

T-Cell Exhaustion and Senescence in Cancer: Regulatory Circuits and Therapeutic State Engineering.

This mechanistic view shifts the therapeutic question from how broadly to activate T cells to which states should be generated, preserved, or rescued and provides a testable basis for state-informed biomarker development and therapeutic design.

Jia-Shu Han, Xiaohong Lyu, Meng-Wei Wu et al. · 0 citations
Review Open access 2026

Interplay between hypoxia and inflammation in cancer progression, therapy resistance, and natural cancer resistance

A simple clearance to resistance framework is proposed that links acute protective stress responses, chronic tumor-promoting adaptation, and naturally evolved cancer resistance, and naturally evolved cancer resistance by cancer resistant subterranean mammals.

Yan-Dong Xu, Yang Zhao · 0 citations
Review Open access 2026

Immune evasion of senescent cells: Mechanisms, pathological significance, and targeted interventions

This review summarizes current evidence suggesting that senescent cells persistence is attributable not only to immune system decline but also to active, cell-intrinsic mechanisms of immune evasion and highlights emerging therapeutic strategies aimed at targeting the immune evasion of senescent cells.

Qikun Ou, Jin-Ran Zhao, Yuanlong Ge et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.